Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension

被引:477
作者
Brandt, Mathias C. [1 ,2 ]
Mahfoud, Felix
Reda, Sara [1 ,2 ]
Schirmer, Stephan H. [4 ]
Erdmann, Erland [2 ]
Boehm, Michael [4 ]
Hoppe, Uta C. [1 ,2 ,3 ]
机构
[1] Paracelsus Med Univ Salzburg, Dept Internal Med 2, A-5020 Salzburg, Austria
[2] Univ Cologne, Dept Internal Med 3, D-50931 Cologne, Germany
[3] Univ Cologne CMMC, Ctr Mol Med, Cologne, Germany
[4] Univ Klinikum Saarlandes, Innere Med Klin 3, Homburg, Germany
关键词
diastolic function; hypertrophy; myocardial mass; renal denervation; resistant hypertension; CARDIOVASCULAR MORBIDITY; DIASTOLIC DYSFUNCTION; MYOCARDIAL FIBROSIS; CLINICAL-OUTCOMES; BETA-BLOCKERS; RISK; MASS; REGRESSION; REDUCTION; MORTALITY;
D O I
10.1016/j.jacc.2011.11.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study investigated the effect of catheter-based renal sympathetic denervation (RD) on left ventricular hypertrophy (LVH) and systolic and diastolic function in patients with resistant hypertension. Background LVH and diastolic dysfunction are associated with elevated sympathetic activity and increased morbidity and mortality. The effect of RD on LVH and LV function is unclear. Methods Forty-six patients underwent bilateral RD, and 18 patients served as controls. Transthoracic echocardiography was performed at baseline, and after 1 month and 6 months. Results Besides reduction of systolic and diastolic blood pressure (-22.5/-7.2 mm Hg at 1 month and -27.8/-8.8 mm Hg at 6 months, p < 0.001 at each time point), RD significantly reduced mean interventricular septum thickness from 14.1 +/- 1.9 mm to 13.4 +/- 2.1 mm and 12.5 +/- 1.4 mm (p = 0.007), and LV mass index from 53.9 +/- 15.6 g/m(2.7) (112.4 +/- 33.9 g/m(2)) to 47.0 +/- 14.2 g/m(2).7 (103.6 +/- 30.5 g/m(2)) and 44.7 +/- 14.9 g/m(2.7) (94.9 +/- 29.8 g/m(2)) (p < 0.001) at 1 month and 6 months, respectively. The mitral valve lateral E/E' decreased after RD from 9.9 +/- 4.0 to 7.9 +/- 2.2 at 1 month and 7.4 +/- 2.7 at 6 months (p < 0.001), indicating reduction of LV filling pressures. Isovolumic relaxation time shortened (baseline 109.1 +/- 21.7 ms vs. 85.6 +/- 24.4 ms at 6 months, p = 0.006), whereas ejection fraction significantly increased after RD (baseline: 63.1 +/- 8.1% vs. 70.1 +/- 11.5% at 6 months, p < 0.001). No significant changes were obtained in control patients. Conclusions Besides the known effect on blood pressure, our study showed for the first time that RD significantly reduces LV mass and improves diastolic function, which might have important prognostic implications in patients with resistant hypertension at high cardiovascular risk. (J Am Coll Cardiol 2012; 59: 901-9) c 2012 by the American College of Cardiology Foundation
引用
收藏
页码:901 / 909
页数:9
相关论文
共 41 条
[1]   Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension [J].
Aeschbacher, BC ;
Hutter, D ;
Fuhrer, J ;
Weidmann, P ;
Delacrétaz, E ;
Allemann, Y .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (02) :106-113
[2]   β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse [J].
Asai, K ;
Yang, GP ;
Geng, YJ ;
Takagi, G ;
Bishop, S ;
Ishikawa, Y ;
Shannon, RP ;
Wagner, TE ;
Vatner, DE ;
Homcy, CJ ;
Vatner, SF .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (05) :551-558
[3]   Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values [J].
Bombelli, Michele ;
Facchetti, Rita ;
Carugo, Stefano ;
Madotto, Fabiana ;
Arenare, Francesca ;
Quarti-Trevano, Fosca ;
Capra, Anna ;
Giannattasio, Cristina ;
Dell'Oro, Raffaella ;
Grassi, Guido ;
Sega, Roberto ;
Mancia, Giuseppe .
JOURNAL OF HYPERTENSION, 2009, 27 (12) :2458-2464
[4]  
Chang N-C, 1996, INT J ANGIOL, V5, P175
[5]   Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis -: Results of a randomized trial [J].
Ciulla, MM ;
Paliotti, R ;
Esposito, A ;
Diez, J ;
López, BA ;
Dahlóf, B ;
Nicholls, G ;
Smith, RD ;
Gilles, L ;
Magrini, F ;
Zanchetti, A .
CIRCULATION, 2004, 110 (05) :552-557
[6]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[7]   REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS - A METAANALYSIS OF 109 TREATMENT STUDIES [J].
DAHLOF, B ;
PENNERT, K ;
HANSSON, L .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (02) :95-110
[8]   Why β-Blockers Should Not Be Used as First Choice in Uncomplicated Hypertension [J].
De Caterina, Alberto Ranieri ;
Leone, Antonio Maria .
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10) :1433-1438
[9]   Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356
[10]   ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS [J].
DEVEREUX, RB ;
ALONSO, DR ;
LUTAS, EM ;
GOTTLIEB, GJ ;
CAMPO, E ;
SACHS, I ;
REICHEK, N .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) :450-458